← Antihypertensives × all-cause mortality

SynthesisHealth technology assessment (Winchester, England)2025

Determining optimal strategies for primary prevention of cardiovascular disease: a synopsis of an evidence synthesis study.

Olalekan A Uthman et al.PubMed ↗Full text ↗Publisher ↗

  • Antiplateletslooks good hereFewer major cardiovascular disease events.Correlation only, not a test of it.
  • Statinslooks good hereFewer composite cardiovascular disease events and deaths.Correlation only, not a test of it.
  • Antihypertensiveslooks good hereFewer composite cardiovascular disease events and deaths.Correlation only, not a test of it.
  • Multifactorial lifestyle interventionslooks good hereFewer composite cardiovascular disease events and deaths.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Antihypertensives went with fewer composite cardiovascular disease events and deaths

−24%−36% to −10%

antihypertensives vs control

Bigger than 7 in 10 for all-cause mortality

As reported

RR 0.76, 95% CI 0.64–0.90 · the paper's word: composite cardiovascular disease events and mortality

Correlation, not cause

Statins went with fewer composite cardiovascular disease events and deaths

−19%−29% to −9%

statins vs control

Bigger than 6 in 10 for all-cause mortality

As reported

RR 0.81, 95% CI 0.71–0.91 · the paper's word: composite cardiovascular disease events and mortality

Correlation, not cause

Multifactorial lifestyle interventions went with fewer composite cardiovascular disease events and deaths

−25%−39% to −8%

multifactorial lifestyle interventions vs control

Bigger than 7 in 10 for all-cause mortality

As reported

RR 0.75, 95% CI 0.61–0.92 · the paper's word: composite cardiovascular disease events and mortality

+4 more in the walkthrough ↓

Who was studied, and how

53,772people with cardiovascular disease, in this paper

Already taking antiplatelets, or nottheir own situation, not assigned

on antiplatelets
control

Antiplatelets went with fewer major cardiovascular disease events−15%

correlation, not a test

Already taking statins, or nottheir own situation, not assigned

on statins
control

Statins went with fewer cardiovascular disease deaths−29%

Statins went with fewer deaths−34%

correlation, not a test

the abstract, start to end

… in 8/17 meta-analyses (relative risks 0.85-0.97), while statins reduced cardiovascular disease mortality (relative risks 0.71-0.89), all-cause mortality (relative risks 0.66-0.93) and major cardiovascular disease events (relative risks 0.59-0.90). sodium-glucose transport …

… that antihypertensives (relative risk 0.76, 95% confidence interval 0.64 to 0.90), intensive blood pressure control (relative risk 0.66, 95% confidence interval 0.46 to 0.96), statins (relative risk 0.81, 95% confidence interval 0.71 to 0.91) and multifactorial lifestyle interventions (relative risk 0.75, 95% confidence interval 0.61 …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Major cardiovascular disease eventsantiplatelets vs control
RR 0.85
Cardiovascular disease mortalitystatins vs control
RR 0.71
All-cause mortalitystatins vs control
RR 0.66
Major cardiovascular disease eventsstatins vs control
RR 0.59
Composite cardiovascular disease events and mortalityantihypertensives vs control
RR 0.760.64–0.90
Composite cardiovascular disease events and mortalitystatins vs control
RR 0.810.71–0.91
Composite cardiovascular disease events and mortalitymultifactorial lifestyle interventions vs control
RR 0.750.61–0.92
StatinsAntihypertensivesAntiplatelet & anticoagulantDiet, exercise & lifestyleAll-cause mortalityAdverse events & safety
1 / 4

2 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40824117